Literature DB >> 16938662

Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis.

Terry K Morgan1, Shuchun Zhao, Karen L Chang, Terri L Haddix, Elisabeth Domanay, P Joanne Cornbleet, Daniel A Arber, Yasodha Natkunam.   

Abstract

Genome-wide expression studies using complementary DNA microarrays recently suggested a number of intriguing candidate genes for distinguishing plasma cell dyscrasias. Our objective was to test select markers using immunohistochemical analysis and a tissue microarray from paraffin-embedded bone marrow core biopsy specimens obtained from 8 patients with monoclonal gammopathy of undetermined significance, 17 with plasmacytoma, 160 with multiple myeloma, and 15 with plasma cell leukemia (PCL). We immunostained serial sections for CD138, CD27, CD56, p27, Ki-67, CD3, and CD20. Each core was scored in duplicate by observers blinded to phenotype and reported as the average percentage of CD138+ cells. The Mann-Whitney U test was used to determine significance between groups. PCL showed significantly less immunostaining for CD27 (P < .01) and p27 (P < .05) compared with plasmacytoma and multiple myeloma. Low CD27 expression also was associated with plasmacytoma progression to multiple myeloma (P <.05). Our results support the hypothesis that low CD27 expression correlates with high-risk disease, including primary PCL and decreased progression-free survival in solitary plasmacytoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16938662     DOI: 10.1309/ELGMGX81C2UTP55R

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  5 in total

Review 1.  Immunophenotyping in multiple myeloma and related plasma cell disorders.

Authors:  Shaji Kumar; Teresa Kimlinger; William Morice
Journal:  Best Pract Res Clin Haematol       Date:  2010-09       Impact factor: 3.020

2.  Prognostic significance of copy-number alterations in multiple myeloma.

Authors:  Hervé Avet-Loiseau; Cheng Li; Florence Magrangeas; Wilfried Gouraud; Catherine Charbonnel; Jean-Luc Harousseau; Michel Attal; Gerald Marit; Claire Mathiot; Thierry Facon; Philippe Moreau; Kenneth C Anderson; Loïc Campion; Nikhil C Munshi; Stéphane Minvielle
Journal:  J Clin Oncol       Date:  2009-08-17       Impact factor: 44.544

3.  Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.

Authors:  Renata Bezdekova; Tomas Jelinek; Romana Kralova; Martin Stork; Petra Polackova; Pavla Vsianska; Lucie Brozova; Jiri Jarkovsky; Martina Almasi; Ivanna Boichuk; Zdenka Knechtova; Miroslav Penka; Ludek Pour; Sabina Sevcikova; Roman Hajek; Lucie Rihova
Journal:  Br J Haematol       Date:  2021-09-09       Impact factor: 8.615

4.  Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.

Authors:  Fei Li; Yan Xu; Ping Deng; Ye Yang; Weiwei Sui; Fengyan Jin; Mu Hao; Zengjun Li; Meirong Zang; Dehui Zhou; Zhimin Gu; Kun Ru; Jianxiang Wang; Tao Cheng; Lugui Qiu
Journal:  Oncotarget       Date:  2015-04-20

5.  Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse.

Authors:  Patryk Krzeminski; Luis A Corchete; Juan L García; Lucía López-Corral; Encarna Fermiñán; Eva M García; Ana A Martín; Jesús M Hernández-Rivas; Ramón García-Sanz; Jesús F San Miguel; Norma C Gutiérrez
Journal:  Oncotarget       Date:  2016-12-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.